@article {4474,
	title = {Pain reduction using transcranial electrostimulation: a double blind "active placebo" controlled trial.},
	journal = {J Rehabil Med},
	volume = {41},
	number = {4},
	year = {2009},
	month = {2009 Mar},
	pages = {256-61},
	abstract = {OBJECTIVE: To examine the efficacy of transcranial electrical stimulation a non-invasive method of reducing pain.

DESIGN: A randomized, double-blind, placebo-controlled trial.

SUBJECTS: A total of 119 patients with chronic pain.

METHODS: Patients were treated with either transcranial electrical stimulation or an active placebo device. Short- and long-term follow-ups were evaluated for treatment efficacy with 4 ordinal scale variables: visual analogue scale (pain level), SLEEP (how often does pain disturb sleep), FREQ (frequency of pain) and MED (frequency of use of medications to relieve pain).

RESULTS: Pain level decreased significantly in the transcranial electrical stimulation-treated group compared with the active-placebo group 3 weeks after the end of treatment (p = 0.0017 between groups). Other parameters did not demonstrate significant differences. Three months after the end of treatment this effect was maintained and other treatment parameters showed similar improvements.

CONCLUSION: Transcranial electrical stimulation is an effective non-invasive method for pain relief. The active placebo device has a powerful effect on reported pain, which diminishes in the long-term. The involvement of possible neural mechanisms is discussed.},
	keywords = {Adult, Aged, Aged, 80 and over, Chronic Disease, Double-Blind Method, Female, Follow-Up Studies, Headache, Humans, Low Back Pain, Male, Middle Aged, Neck Pain, Pain Management, Pain Measurement, Transcranial Magnetic Stimulation, Treatment Outcome},
	issn = {1651-2081},
	doi = {10.2340/16501977-0315},
	author = {Gabis, Lidia and Shklar, Bentzion and Baruch, Yael Kesner and Raz, Raanan and Gabis, Eddy and Geva, Daniel}
}
@article {4472,
	title = {Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review.},
	journal = {Dev Med Child Neurol},
	volume = {51},
	number = {8},
	year = {2009},
	month = {2009 Aug},
	pages = {580-92},
	abstract = {AIM: Essential fatty acids (EFAs), also known as omega-3 and omega-6 fatty acids, have been claimed to have beneficial effects as a treatment for attention-deficit-hyperactivity disorder (ADHD). Animal experiments have provided information about the role of EFA in the brain, and several mechanisms of EFA activity are well known. The current review provides an updated, systematic overview of the theory and use of EFA in ADHD.

METHOD: Clinical studies and review papers of EFA blood levels and EFA supplementation trials in children with ADHD were researched in the Medline PubMed database. Additional studies were found from the references of these reports.

RESULTS: Children with ADHD present lower levels of blood EFAs, and open-label EFA supplementation trials in ADHD raise EFA blood levels and improve symptoms of ADHD. Randomized controlled trials, however, have generally been unsuccessful in demonstrating any behavioural treatment effects.

INTERPRETATION: Current findings do not support the use of EFA supplements as a primary or supplementary treatment for children with ADHD.},
	keywords = {Adolescent, Attention Deficit Disorder with Hyperactivity, Brain, Child, Child, Preschool, Dietary Supplements, Fatty Acids, Omega-3, Fatty Acids, Omega-6, Humans},
	issn = {1469-8749},
	doi = {10.1111/j.1469-8749.2009.03351.x},
	author = {Raz, Raanan and Gabis, Lidia}
}
@article {4473,
	title = {The influence of short-chain essential fatty acids on children with attention-deficit/hyperactivity disorder: a double-blind placebo-controlled study.},
	journal = {J Child Adolesc Psychopharmacol},
	volume = {19},
	number = {2},
	year = {2009},
	month = {2009 Apr},
	pages = {167-77},
	abstract = {Essential fatty acids (EFA) are needed for normal sensory, cognitive, and motor function. The EFA blood profile seems to be different in children with attention-deficit/hyperactivity disorder (ADHD) as compared to matched controls. Previous open EFA supplementation trials were successful in demonstrating significant therapeutic effects in this population, whereas most of the randomized controlled trials failed to show any benefit over placebo. The current randomized, double-blind, placebo-controlled trial tested the influence of short-chain EFA supplementation on ADHD children, using parent and teacher questionnaires and a computerized continuous performance test. A total of 73 unmedicated children aged 7-13 years with a diagnosis of ADHD participated in the study; 63 children completed the study. The EFA supplement contained 480 mg of linoleic acid and 120 mg of alpha-linolenic acid, and the placebo contained 1000 mg of vitamin C (daily amounts); both were given for a 7-week supplementation period. Analysis of variance for repeated measures revealed that both treatments ameliorated some of the symptoms, but no significant differences were found between the groups in any of the treatment effects.},
	keywords = {Adolescent, alpha-Linolenic Acid, Attention Deficit Disorder with Hyperactivity, Child, Dose-Response Relationship, Drug, Double-Blind Method, Drug Combinations, Fatty Acids, Essential, Female, Humans, Linoleic Acid, Male, Psychological Tests, Psychomotor Performance, Questionnaires},
	issn = {1557-8992},
	doi = {10.1089/cap.2008.070},
	author = {Raz, Raanan and Carasso, Rafael L and Yehuda, Shlomo}
}
